Počet záznamů: 1
Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats
- 1.
SYSNO ASEP 0474019 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats Tvůrce(i) Sedláková, L. (CZ)
Čertíková - Chábová, V. (CZ)
Doleželová, Š. (CZ)
Škaroupková, P. (CZ)
Kopkan, L. (CZ)
Husková, Z. (CZ)
Červenková, L. (CZ)
Kikerlová, S. (CZ)
Vaněčková, Ivana (FGU-C) RID, ORCID
Sadowski, J. (PL)
Kompanowska - Jezierska, E. (PL)
Kujal, P. (CZ)
Kramer, H. J. (DE)
Červenka, L. (CZ)Zdroj.dok. Clinical and Experimental Hypertension - ISSN 1064-1963
Roč. 39, č. 2 (2017), s. 183-195Poč.str. 13 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova chronic kidney disease ; endothelin system ; hypertension ; renin–angiotensin system ; 5/6 nephrectomy Vědní obor RIV FA - Kardiovaskulární nemoci vč. kardiochirurgie Obor OECD Cardiac and Cardiovascular systems Institucionální podpora FGU-C - RVO:67985823 UT WOS 000396749000014 EID SCOPUS 84859374582 DOI 10.1080/10641963.2016.1235184 Anotace Early addition of endothelin (ET) type A (ETA) receptor blockade to complex renin–angiotensin system (RAS) blockade has previously been shown to provide better renoprotection against progression of chronic kidney disease (CKD) in Ren-2 transgenic hypertensive rats (TGR) after 5/6 renal ablation (5/6 NX). In this study, we examined if additional protection is provided when ETA blockade is applied in rats with already developed CKD. Methods: For complex RAS inhibition, an angiotensin-converting enzyme inhibitor along with angiotensin II type 1 receptor blocker was used. Alternatively, ETA receptor blocker was added to the RAS blockade. The treatments were initiated 6 weeks after 5/6 NX and the follow-up period was 50 weeks. Results: When applied in established CKD, addition of ETA receptor blockade to the complex RAS blockade brought no further improvement of the survival rate (30% in both groups), surprisingly, aggravated albuminuria (588 ± 47 vs. 245 ± 38 mg/24 h, p < 0.05) did not reduce renal glomerular injury index (1.25 ± 0.29 vs. 1.44 ± 0.26), did not prevent the decrease in creatinine clearance (203 ± 21 vs. 253 ± 17 µl/min/100 g body weight), and did not attenuate cardiac hypertrophy to a greater extent than observed in 5/6 NX TGR treated with complex RAS blockade alone. Conclusions: When applied in the advanced phase of CKD, addition of ETA receptor blockade to the complex RAS blockade brings no further beneficial renoprotective effects on the CKD progression in 5/6 NX TGR, in addition to those seen with RAS blockade alone. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2018
Počet záznamů: 1